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E-mail address: henis@post.tau.ac.il (Y.I. Henis).Transforming growth factor-b (TGF-b) and bone morphogenetic protein (BMP) cytokines participate
in a multiplicity of ways in the regulation of numerous physiological and pathological processes.
Their wide-ranging biological functions are controlled by several mechanisms, including regulation
of transcription, complex formation among the signaling receptors (oligomerization) and with co-
receptors, binding of the receptors to scaffolding proteins or their targeting to speciﬁc membrane
domains. Here, we address the generation of TGF-b and BMP receptor homo- and hetero-oligomers
and its roles as a mechanism capable of fast regulation of signaling by these crucial cytokines. We
examine the available biochemical, biophysical and structural evidence for the ternary structure
of these complexes, and the possible roles of homomeric and heteromeric receptor oligomers in
signaling.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Cytokines of the transforming growth factor-b (TGF-b) superfam-
ily mediate and regulate cellular homeostasis, including embryonic
development, differentiation, proliferation, tissue regeneration,
immune surveillance, angiogenesis and apoptosis [1–7]. Prominent
among the superfamily, which includes in mammals over 30 mem-
bers sharing a common cystine knot structure, are TGF-bs, bone
morphogenetic proteins (BMPs), growth and differentiation factors
(GDFs), Müllerian inhibiting substance (MIS), nodals, activins and
inhibins [5,8–11]. TGF-b superfamily signaling has been shown to
play diverse roles in a variety of human diseases, including cancer
(functioning as both tumor suppressors and tumor promoters), vas-
cular and skeletal diseases, primary pulmonary hypertension, and
predisposition to angioproliferative disorders [12–17]. Signaling by
TGF-b superfamily hormones is mediated by type I and type II recep-
tors endowedwith serine/threonine kinase activity [5,11,18,19]. This
signaling is subject to modulation by several groups of co-receptors:
the type III TGF-b receptor (TbRIII, or betaglycan) and endoglin; the
glycosylphosphatidylinositol-linked family of repulsive guidance
molecules (RGM); and the EGF-CFC protein family [3,11,16,20–25].
The focus of this review is on complex formation between the type
I and type II receptors, found to be necessary and sufﬁcient for Smad
and numerous other non-Smad signaling responses mediated by
TGF-b or BMP/GDF ligands.cal Societies. Published by ElsevierSignaling by members of the TGF-b superfamily is triggered by
binding of the cytokine to a heteromeric type I/type II receptor
complex, leading to phosphorylation and activation of the type I
receptor by the respective type II receptor kinase [5,26–28]. The
activated type I receptors phosphorylate the receptor-regulated
Smads (R-Smads) at two C-terminal serine residues, followed by
association of R-Smad with the common mediator Smad4 and
translocation into the nucleus, where in cooperation with other
transcription factors they induce both positive and negative
transcriptional regulation of target genes in a cell-context depen-
dent manner [7,11,27–30]. Among the R-Smads, Smad2 and 3,
are activated by TGF-b/activin/nodal ligands, whereas Smad1, 5
and 8 are stimulated by BMP/GDF/MIS [27,29]. Yet, this division
is not absolute and some promiscuity in cytokine/R-Smad pairing
can occur [31–34]. TGF-b superfamily cytokines can also trigger
numerous non-Smad pathways, including extracellular-signal
regulated kinase, c-Jun N-terminal kinase, phosphatidylinositol-
3-kinase, p38 mitogen-activated protein kinase, Src, and pathways
involving Rho GTPases [35–40].
Aside of the basic activation or inhibition of the receptors by var-
ious agonists and antagonists, signaling in the TGF-b superfamily is
controlled by a number of regulatory mechanisms, which operate
on different time scales and at distinct subcellular localizations.
These include heteromeric and homomeric complex formation
among the signaling receptors, interactions with modulatory
co-receptors or scaffolding proteins, intracellular trafﬁcking events
(endocytosis and polarized sorting), and transcriptional activation
or inhibition [1,11,15,16,23,41–44]. Of these, oligomericB.V. Open access under CC BY-NC-ND license.
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ligands provide a regulatory mechanism capable of fast temporal
response already at the plasma membrane. In the present review,
particular attention is devoted to this mechanism in the context
of TGF-b and BMP receptors. We focus on homo- and hetero-oligo-
merization between the type I and type II TGF-b receptors (TbRI,
also known as ALK5, and TbRII) and among the respective BMP
receptors, and discuss the possible functions of the oligomeric
interactions in the regulation of signaling by these cytokines.
2. Biochemical studies on the assembly of TGF-b and BMP
receptor oligomers
2.1. Ligand binding and oligomerization of TGF-b receptors
Historically, initial characterization of ligand binding to the
TGF-b receptors was achieved by binding/crosslinking of iodinated
TGF-b to the cell-surface receptors. These experiments pointed to
marked differences between the binding characteristics of different
TGF-bs to the receptors, highlighting distinct roles of TbRI and TbRII
in ligand-binding interactions [5,26,45,46]. Thus, TGF-b1 and
TGF-b3 were shown to bind with high afﬁnity (pM range) to sin-
gly-expressed TbRII but not to TbRI. This pattern was altered in cells
co-expressing TbRI and TbRII; under these conditions, TGF-b1 and
TGF-b3 exhibited high-afﬁnity binding not only to TbRII but also
to TbRI. Based on these ﬁndings, it was proposed that assembly of
the signal-transducing TGF-b/TbRI/TbRII complex is sequential
and cooperative [11,26]. According to the proposed model, TGF-b
initially binds with high-afﬁnity to TbRII, and TbRI is then recruited
to the ligand/TbRII complex. It seems, therefore, that this assembly
modewould be better described as ordered-sequential, because the
highly different afﬁnities of TbRII and TbRI to the ligand dictate a
sequential order of complex assembly. Notably, a different pattern
of receptor interactions is observed for TGF-b2, which lacks high
afﬁnity to either singly expressed TbRII or TbRI, and requires pre-
sentation by TbRIII for high afﬁnity binding to TbRII [47,48]. The
weak binding of TGF-b2 to TbRII results from the respective replace-
ment of Arg25, Val92 and Arg94 (present in TGF-b1 and TGF-b3) by
Lys25, Ile92 and Lys94 [49,50]. Co-expression of TbRI with TbRII or
with its alternatively-spliced variant, TbRIIB, strongly enhances the
afﬁnity of TGF-b2 to the co-expressed receptors, suggestive of
mutual complex formation [51–53]. The absence of high afﬁnity
binding of TGF-b2 to either singly expressed TbRI or TbRII makes
an ordered-sequential heterocomplex assembly mechanism highly
unlikely; a random-sequential assembly path, where TGF-b2 may
bind initially to either TbRII or TbRI and then recruit the second
receptor, is a more likely possibility for this ligand. The low afﬁnity
of TGF-b2 to TbRII or TbRI alone would lead to inherently weak
interactions of the receptors with the ligand or with each other in
solution. However, the binding/assembly process can be assisted
by the anchorage of the receptors in the plasma membrane; the
enhanced local densities of the receptors in the membrane could
lead to ‘‘reduction of dimensionality’’, increasing the experimen-
tal-observed afﬁnity to the ligand due to the avidity effect, medi-
ated by the concomitant binding of the ligand to proximal
receptors situated at the cell surface [54]. Another possibility is that
in cells, a fraction of the full-length receptors can oligomerize into
preformed complexes (PFCs) that contain both receptor types
([55,56]; see Section 3). PFCs, whether formed alone or in associa-
tion with co-receptors or other scaffolding proteins, could enhance
the avidity of TGF-b ligands to cell-surface receptors, due to the
higher probability for concomitant binding of the multivalent
ligand to several sites.
The cooperative nature of TbRI recruitment to ligand-bound
TbRII is another important feature in the assembly of TGF-breceptor hetero-oligomers that should be considered. Crystallo-
graphic structural data (see Section 4) provide the rationale
underlying the cooperative model proposed for ligand-induced
complex assembly [57–62]. Those studies demonstrated that a
composite interface, generated by the ligand and TbRII in the bin-
ary TGF-b/TbRII complex, binds TbRI with high afﬁnity by virtue
of its direct interaction with both the ligand and TbRII on that
interface (see Fig. 4 in Section 4). The membrane tethering of
the receptors (reduction of dimensionality) may contribute to
further increase the recruitment of TbRI to the TGF-b/TbRII com-
plex by avidity effects, as proposed for BMP receptors [54,63,64].
Nevertheless, an allosteric assembly model that incorporates a
conformational change induced either in the ligand [65] or in
TbRII seems unfeasible, given the fact that no signiﬁcant confor-
mational changes in these proteins upon binding are evident in
the crystal structures [61,62]. In the absence of detailed structural
information for ligand-free TbRI, however, the possibility of a con-
formational change in TbRI within the hetero-oligomer cannot be
excluded.
Strong additional support for the sequential and cooperative
assembly mode comes from studies in vitro on the interactions
between TGF-bs and the extracellular domains (EDs) of TbRI and
TbRII. Binding of the TbRII ED in solution to biosensor-coupled
TGF-bs [66] using surface plasmon resonance (SPR) conﬁrmed that
the TbRII ED has a much higher afﬁnity for TGF-b1 and TGF-b3
(100 nM) than for TGF-b2, whose binding was below the limit
of detection. The afﬁnities for TGF-b1/b3 and TGF-b2 in the SPR
studies were, however, two orders of magnitude lower than those
measured by binding/crosslinking of iodinated TGF-bs to receptors
situated in the plasma membrane. This discrepancy was partially
resolved in subsequent studies, which employed a coiled-coil cap-
ture system to achieve oriented coupling of the TbRII ED to the
biosensor surface [67], resulting in a signiﬁcant enhancement of
the apparent afﬁnities of soluble TGF-bs for the sensor-bound
TbRII ED, bringing them to the same range measured for the bind-
ing of iodinated TGF-bs to the cellular receptors. This was attrib-
uted to avidity effects, as the dimeric ligand now binds to two
TbRII EDs localized close to each other on the biosensor surface.
In line with this suggestion, iodinated TGF-b1 and TGF-b3 exhib-
ited high-afﬁnity binding to TbRII ED fused to dimeric Fc antibody
segments attached to protein A-coated plates [53]. Moreover, arti-
ﬁcial dimerization of TbRII ED enhanced the binding of the di-
meric TbRII EDs to TGF-b ligands immobilized on the biosensor
surface [66,68]. Accordingly, reporter gene assays showed that
the soluble TbRII ED dimers exhibit improved ability to inhibit
TGF-b-mediated transcriptional activation [53,68]. Of note, some
differences between afﬁnity values measured at the cell surface
and in SPR experiments may stem from diminished ﬂexibility of
the ligand upon its immobilization to the sensor surface in SPR
experiments. This might limit the ability of the soluble TbRII ED
to access binding sites on the ligand, further reducing the binding
afﬁnity. Based on analogous experiments, similar conclusions
were reached for the BMP receptors (see Section 2.2). Notably,
the ordered-sequential cooperative oligomerization model is in
line with the substantial increase (over two orders of magnitude)
in the afﬁnity of the TbRI ED to biosensor-coupled TGF-bs in the
presence of an excess of TbRII ED, conditions under which the li-
gands at the sensor surface are associated with TbRII ED [61,62].
The ordered-sequential cooperative model for TGF-b receptor–li-
gand interactions is also supported by native gel assays [69] of
the complexes formed in solution between the EDs of TbRII, TbRI
and TGF-bs, and by the ﬁnding that although TGF-b2 has negligi-
ble binding to soluble Fc-fused TbRII EDs, it displays high afﬁnity
to the same receptors when the solution contains also Fc-fused
soluble TbRI ED [53].
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The TGF-b and BMP receptors share major features, such as
transactivation of the type I by the type II receptor, and a 2:2:2 stoi-
chiometry of the heteromeric receptor–ligand complex. The two
receptor systems, however, also display distinct differences. The
binding afﬁnities of BMP/GDF ligands for their plasma membrane
receptors are signiﬁcantly weaker (by 2–3 orders of magnitude)
than those of TGF-b ligands (reviewed in [5,54]), possibly due to
dissimilarities between the binding interfaces of the ligand/type II
receptor pairs. An additional reason for the lower afﬁnity of BMPs
may reside in subtle differences in the pairing of the b1/b2 loop
and/or the b4/b5 loop extension of the type I receptors with their
ligands [61,62]. The weaker binding may underlie the greater pro-
miscuity of BMP ligand/receptor interactions relative to that of
TGF-b ligands, as indicated by ligand binding/crosslinking studies
in cells and SPR experiments in vitro (reviewed in [15,16,23,54]).
This is exempliﬁed by the reports that in binding studies conducted
either on cells [70–77] or on isolated receptor EDs [54,64,78–80],
the numerous receptor subtypes that bind BMP/GDFs exhibited
mixed afﬁnities for the ligands, depending on the speciﬁc combina-
tions of type I/type II receptors in conjunction with a given ligand.
In most cases, BMP/GDFs bind with higher afﬁnity to type I recep-
tors, but the difference between their afﬁnities to the two receptor
types is much less than that observed in the TGF-b receptor system.
Thus, BMP-2 and GDF-5 bind to BMPRII, ActRII, and ActRIIB with
10- to 50-fold lower afﬁnities than to BMPRIA (ALK3) and BMPRIB
(ALK6), which bind these ligands with higher (nM range) afﬁnities
[54,79]. A different situation is presented by BMP-7, which binds
to ActRII, ActRIIB and BMPRIB with intermediate afﬁnities, but
displays low afﬁnities to BMPRII and BMPRIA [54,73,74]. Thus, the
assembly of heteromeric BMP receptor signaling complexes is
characterized by a mixed (i.e., both ligand-dependent and recep-
tor-dependent) and intermediate tendency for a speciﬁc sequential
order [54]. It should be noted that this mechanism appears to be
non-cooperative, since no signiﬁcant conformational changes were
detected in either the ligand or the receptors upon complex forma-
tion, and no direct interaction was found between the EDs of BMP
receptors ([64,81,82]; see Fig. 4). It seems, rather, that avidity pro-
vides a major contribution to the ligand-mediated assembly of
BMP-receptor complexes [54]. Several factors may contribute to
the elevated avidity. These include: (i) reduction in dimensionality
due to tethering of the full-length receptors to the membrane, in
line with the increase in the apparent afﬁnity upon coupling of
the receptor EDs instead of the ligands to the SPR biosensor surface
[54,64,78–80]; (ii) the increase in the number of sites forming con-
tact with the ligand (avidity vs. afﬁnity) upon homodimerization of
the receptors, and following formation of heterotetrameric receptor
complexes with the dimeric ligand [54,81,82]; and (iii) interactions
between the cytoplasmic domains (CDs) [83] and/or the transmem-
brane (TM) domains of the full-length receptors at the cell surface.
Thus, the formation of BMPRII/BMPRI hetero-oligomers is impaired
by truncation of the BMPRII CD [83], suggesting that the CDs of the
BMP receptors participate in their heteromeric interactions. The
formation of PFCs amongst BMP receptors can further intensify
the avidity effects and may have important functions in signaling
([83]; further discussed in Section 4).
3. Complex formation among TGF-b and BMP receptors in live
cells: regulation and dynamics
To investigate interactions between TGF-b and BMP receptors
situated in their native milieu, i.e., the plasma membrane, biophys-
ical and signaling studies on live cells are needed. An added advan-
tage of such studies is that they can reveal potential effects of
modulatory factors present in the cellular environment.3.1. TGF-b receptors
A variety of experimental methods have been used to study the
formation of homomeric and heteromeric complexes involving
TbRI and TbRII, both without and with ligands. Initial studies
employed radioligand binding/crosslinking, sequential immuno-
precipitation from metabolically labeled cells, co-immunoprecipi-
tation, or yeast two-hybrid assays to assess TGF-b receptor
oligomerization; the experiments disclosed the existence of
ligand-bound TbRI/TbRII heterocomplexes, and revealed low but
detectable interactions between TbRI and TbRII or their CDs
already without ligand [5,26,46,55,71,84–86]. Sequential immuno-
precipitation experiments and semi-quantitative immunoﬂuores-
cence co-patching studies (see following paragraph) employed
coexpressed TbRI and/or TbRII carrying different epitope tags (an
HA-tagged receptor coexpressed with a myc-tagged receptor) to
assess TGF-b receptor oligomerization in intact cells. These studies
revealed homomeric interactions for both receptor types in the
absence of ligand, which in the case of TbRII were enhanced by
TGF-b1 [87–89].
To obtain a more quantitative measure for these interactions,
we have developed and utilized biophysical approaches that make
it possible to characterize the dynamic nature of receptor interac-
tions and to quantify the extent of homomeric and heteromeric
complex formation among TGF-b superfamily receptors. One
approach was to incorporate a computerized digital analysis into
the immunoﬂuorescence co-patching method [90], which is
described in Fig. 1. This analysis ([56]; Fig. 2A) demonstrates that
TbRII displays a signiﬁcant percentage of homodimerization
(25%), which increases to 36% following TGF-b1 binding. More
extensive homodimerization, which is ligand-independent, is
displayed by TbRI (40%). This homodimerization is ligand-
independent, consistent with the undetectable binding of TGF-b
to TbRI in the absence of TbRII. Heteromeric TbRI/TbRII PFCs
(25%) are also detected. Importantly, heteromeric complex forma-
tion is dramatically increased (to 45%) after TGF-b1 binding
(Fig. 2A).
A second approach that we have developed [91] and applied re-
cently to study TGF-b receptor oligomerization is patch/FRAP (ﬂuo-
rescence recovery after photobleaching) [56]. In this FRAP variation
(described in Fig. 3), one receptor is immobilized by crosslinking
with primary and secondary IgGs (patching); the effects on the lat-
eral diffusion of a coexpressed uncrosslinked receptor, labeled by
Fab’ fragments coupled to another ﬂuorophore [56,91] or fused
to a ﬂuorescent protein [92,93], are then measured by FRAP. Nota-
bly, this method can establish whether the receptor complexes are
stable or transient on the FRAP time scale (minutes for TM pro-
teins). When the lifetime of the complex with the immobilized
receptor exceed the typical FRAP recovery time (i.e., relatively
stable complexes), immobilization of one receptor will reduce
the mobile fraction (Rf) of its coexpressed uncrosslinked counter-
part (Fig. 3). This occurs because bleached molecules of the
uncrosslinked receptor do not appreciably dissociate from the
immobilized patches during the FRAP measurement. On the other
hand, complexes that are transient on the FRAP time scale undergo
several dissociation/association cycles during the FRAP experi-
ment; therefore, the Rf of the uncrosslinked receptor will not be
affected, while its apparent lateral diffusion coefﬁcient (D) will
be reduced. When Rf is affected (stable complexes), it is possible
to derive directly the % of hetero-oligomerization (complex
formation among different receptors) from the fractional reduction
in Rf of the uncrosslinked receptor. Thus, when Rf is reduced from
0.80 to 0.60 one can calculate that the % oligomeriza-
tion = 100  (0.20/0.80) = 25%. To calculate homodimer formation,
a statistical correction should be introduced due to the formation
of same-tag dimers; for coexpressed versions of the same receptor
Fig. 1. Principle of immunoﬂuorescence co-patching. One TGF-b (or BMP) receptor with an myc-tagged ED and another receptor with an HA tag (both of the same receptor
type, for measuring homomeric complexes, or from different receptors, for measuring heteromeric interactions) are coexpressed, and labeled/patched at 4 C by murine anti-
myc (Mamyc) and rabbit anti-HA (RaHA) IgGs, followed by goat IgG (GaM and GaR, coupled to green and red ﬂuorophores, respectively) (see key on right). (A) Non-
interacting receptors. Separate green and red patches are formed. (B) Receptors that form heterocomplexes to some extent. The receptors in the heterocomplexes are swept
into shared patches, which appear yellow upon superposition of the red and green images. Whether a green and a red patch are colocalized or not is digitally determined by
computerized analysis, based on the distance between the centers of mass of the two patches, which are deﬁned as overlapping for distances below 0.2 lm [90]. The % co-
patching is deﬁned as the percentage of e.g. green patches that overlap with red patches [for the green labeled receptors, this is given by 100  Yellow/(Yellow + Green)]. The
calculated % co-patching is corrected by subtracting the percentage of random co-localization in the same image, derived by superimposing the green image from one region
of interest on the red image of a shifted neighboring region. In addition, the experimentally measured non-speciﬁc co-patching between the receptor of interest and an
unrelated membrane protein can be subtracted as an additional control [56,90]. (C) Homodimeric receptors. Since the receptors differ only in the tag, both same-tag and
different-tag complexes are formed, reducing the % co-patching detected. Statistical considerations [56,108] show that for homodimers, the probabilities for the formation of
tagged dimers are 1:2:1 for myc/myc (green-labeled), myc/HA (green and red) and HA/HA (red) pairs, respectively. Thus, 2/3 of the green-labeled patches will also contain
red-labeled receptors (and vice versa), and the % co-patching should be multiplied by a factor of 3/2 to obtain the actual % homodimerization. No such correction is needed for
heterocomplex formation. The algorithms for computerized quantiﬁcation of the percentage of co-patching have been described [90].
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probabilities for homodimerization are 1:2:1 for myc/myc, myc/
HA, and HA/HA-containing dimers, respectively. Upon patching of
e.g. HA-TbRI, only the myc-TbRI molecules in the mixed-tag
(myc/HA) dimers would undergo immobilization. Furthermore,
since myc/myc dimers contain two myc tags per dimer, they are
labeled by anti-myc Fab’ at twice the intensity of myc/HA dimers,
which contain only one myc tag per dimer. As a result, the % reduc-
tion in Rf is only half of the % dimerization, which can be calculated
as % dimerization = (% reduction in Rf)  2. A useful feature of the
patch/FRAP technique is that it provides information on complex
formation only among the mobile receptor population, unlike
immunoﬂuorescence co-patching, in which all cell-surface recep-
tors are measured.
Studies on TbRI and TbRII complex formation using patch/FRAP
[56] showed, for all complexes (homomeric or heteromeric, with or
without TGF-b) a reduction in Rf with no effect on D. These ﬁndings
indicate that the receptor complexes are stable, at least on the time
scale of the FRAP experiments (minutes). This enabled us to calcu-
late the percentage of both homo- and hetero-oligomerization
among TGF-b receptors; the results were in the same range mea-
sured in the co-patching experiments (Fig. 2A). Moreover, there
are several indications that the major features of the above results
are valid also for low expression levels and for the endogenous
receptors. First, ultracentrifugation-based size determination of
detergent-solubilized 35S-labeled endogenous TbRI and TbRIIrevealed the presence of major populations of SDS-sensitive homo-
dimers already prior to ligand binding, and showed they dimerize
at an early stage (in the ER). In addition, these experiments
detected a high amount of heteromeric TbRI/TbRII complexes in
the presence of TGF-b1, at a size consistent with ligand-bound het-
erotetramers [55,89]. Notably, the fact that these heteromeric
complexes were retained for hours throughout the prolonged cen-
trifugation on the sucrose gradients [56] is in line with the stable
nature of the complexes as revealed by the patch/FRAP studies
(Fig. 2A). A second independent validation of the interactions de-
tected by the co-patching and patch/FRAP studies comes from
the single-cell, microscopic nature of these measurements, which
enables to select single cells under the microscope on the basis
of their expression level. The cells routinely selected for measure-
ment exhibited low to medium expression levels (4000–20000
receptors/cell), whose lower limit overlaps with the upper scale re-
ported for endogenous TbRI and TbRII expression in cells [94].
Within this range, the results obtained for low- and medium-
expressing cells were indistinguishable.
Oligomerization of TGF-b receptors was recently investigated
by single-molecule imaging of TGF-b receptor-GFP chimeric pro-
teins [95–97]. The analysis was based either on the ﬂuorescence-
intensity distribution of diffraction-limited objects (interpreted to
reﬂect monomers vs. low-order oligomers) or on the number of
bleaching steps of the ﬂuorescent objects (assuming one-step
bleaching kinetics for a monomer, and two-step bleaching kinetics
Fig. 2. Homomeric and heteromeric complex formation among TGF-b and BMP receptors. Data were calculated as described in Figs. 1 (co-patching, designated Co-P) and 3
(patch/FRAP, designated P.F.; see Fig. 3 for patch/FRAP description). For all co-patching data, non-speciﬁc co-patching was subtracted. Results are from the references
indicated above each group of data. They are presented as % oligomerization, which gives a direct measure of heteromeric complexes; in the case of homomeric complexes, it
stands for % homodimerization after statistical corrections as described in the legends of Figs. 1 (co-patching) and 3 (patch/FRAP). No statistical correction was applied to
BMPRIA/BMPRIB oligomerization, because this complex is comprised of two different receptors. Note that for BMP receptor hetero-oligomerization, oligomerization
percentages are derived only from immunoﬂuorescence co-patching, because the transient nature of BMP receptor heterocomplexes does not allow the extent of their
oligomerization to be calculated from patch/FRAP. This limitation arises because the reduction in the lateral diffusion coefﬁcient (D), which is the hallmark of transient
interactions in patch/FRAP experiments, is a complex function of both the equilibrium binding and the association/dissociation kinetics.
Fig. 3. Principle of patch/FRAP experiments. One of the two coexpressed receptors carrying different extracellular epitope tags is crosslinked into patches (e.g., red secondary
IgG), becoming laterally immobile. The other is labeled by monovalent ﬂuorescent Fab’ fragments (green in the diagram) [56,91,110] or by a ﬂuorescent protein tag [92,93].
Dual-labeled cells are identiﬁed under the microscope, and FRAP experiments are conducted on the Fab’ ﬂuorescence (green in this case). (A) Non-interacting receptors. The
IgG-crosslinked receptors become immobile, but since the Fab’-labeled receptors do not bind to the immobilized clusters their lateral diffusion is not affected. (B) Interacting
receptors. At any time point, a fraction of the Fab’-labeled receptors is in complex with the IgG-crosslinked, immobilized receptors. Depending on whether these complexes
are stable or transient on the FRAP time scale, the interaction reduces either the mobile fraction (Rf) or the lateral-diffusion coefﬁcient (D) of the Fab’-labeled receptors,
respectively [56,91,110].
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low homodimerization levels in the absence of ligand, which in-
crease for TbRII after TGF-b1/b3 binding [95], but curiously also
for TbRI in the presence of TGF-b3 [97]. Since TbRI alone does
not bind TGF-b3, the latter observation suggests that the TbRI-
GFP homodimerization measured in these experiments is alteredby interactions with non-ﬂuorescent endogenous TbRII (which
binds TGF-b3), and most likely also with endogenous TbRI, which
would mask homodimer formation among TbRI-GFP molecules.
Notably, the post-transfection expression times employed in the
single molecule studies on GFP-tagged receptors were short (typi-
cally 3–4 h), to ensure low expression levels; the levels reported
Fig. 4. Hetero-oligomeric complexes of the ligand-bound EDs of TGF-b and BMP receptors. (A) Dimeric TGF-b bound by two TbRI and two TbRII molecules. Each TbRII binds,
mainly by polar interactions, to the ‘‘ﬁngertip’’ epitope of one TGF-b protomer. The TbRII and both TGF-b subunits form a composite binding interface for TbRI, enabling it to
interact with TbRII as well as with both monomers of TGF-b. (B) BMP is bound by BMPRIA at the ‘‘wrist’’ epitope, and by ActRIIB at the ‘‘knuckle’’ epitope. In contrast to the
TGF-b receptor–ligand complex, the EDs of type I and type II BMP receptors do not contact each other in the ternary complex. Images were produced using PyMOL molecular
graphics based on X-ray crystallographic data from PDB ID 3KFD for the TGF-b receptor EDs in complex with TGF-b [61], and from PDB ID 2H64 for the equivalent BMP
receptor–ligand ternary complexes [82]. Reproduced with permission from [141].
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expression for TbRI and TbRII, and considerably less than the
expression levels of endogenous TbRIII [94]. It was proposed that
these low expression levels result in much lower dimerization.
However, in these studies, the results were recorded as the per-
centage of dimeric (d) vs. monomeric (m = 100  d) particles.
Therefore, the numbers of dimeric particles should be multiplied
by 2 to yield the percentage of GFP-labeled molecules in dimers
[% dimerization = 2d/(100 + d)]. Once such a correction is intro-
duced, the % homodimerization of TbRII in HeLa cells in the ab-
sence of ligand ranges from 12% (calculated based on bleaching
steps analysis) to 25% (intensity distribution analysis) [95]. The
lower values derived from bleaching steps analysis suggest poten-
tial masking of some bleaching events by the fast bleaching kinet-
ics, leading to underestimation of homodimer formation. In the
presence of TGF-b1, the two analyses (intensity distribution and
bleaching steps) recorded an increase in the dimerization of TbRII
to 59% and 47%, respectively [95]. These values are in line with
the results of the co-patching and patch/FRAP studies (Fig. 2A),
which indicated that TbRII undergoes low but signiﬁcant homodi-
merization in the absence of ligand, which increases upon TGF-b1
binding. For TbRI-GFP homodimerization, analogous calculations
based on the reported bleaching steps analysis data [96] yield
20–28% in HeLa, MCF7 or R1B cells. These values are somewhat
lower than those derived from patch/FRAP and co-patching studies
(Fig. 2A), possibly because the number of bleaching steps is under-
estimated due to fast bleaching kinetics. Other factors that might
also interfere with these measurements are the reduced activity
(by 4-fold) of TbRI-GFP relative to TbRI-HA, and a failure to reach
steady state in the cellular distribution/oligomerization of TbRI-
GFP during the short interval between transfection and detection,
which is similar to the half-life of TbRI in the ER (3 h) [98].
To investigate the functions of distinct domains in the regula-
tion of homomeric and heteromeric TGF-b receptor interactions,
a series of TbRI and TbRII truncation, deletion and alanine-replace-
ment mutants were analyzed by co-patching and patch/FRAP [56].Homodimerization of TbRII was found to depend on amino acids
200–220 in the juxtamembrane region of the CD. These interac-
tions are important for TbRII dimerization, because without ligand,
the ED of TbRII was found to be monomeric [89,99]. The CD of TbRI
was dispensable for homodimerization, but contributed (along
with a C-terminal region in TbRII) to TbRI/TbRII hetero-oligomeri-
zation. These ﬁndings are in line with the report that joint overex-
pression of TbRI and TbRII CDs, or of these receptors lacking their
EDs, results in constitutive activation, implying interaction
between their CDs [100,101].
The existence of homomeric and heteromeric TGF-b receptor
oligomers in the absence of ligand (PFCs), and the increased oligo-
merization induced by ligand binding, pose questions concerning
the functions of the different complexes. Whereas the formation
of heterocomplexes is clearly a precondition for the activation of
TbRI by TbRII [5,18,26,46,102], the role of homodimerization is less
obvious. Evidence from a number of studies suggests that TbRI
homodimerization may be required for signaling, and that homo-
meric interactions of TbRII have modulatory functions. In the case
of TbRI, studies employing a chimera of the erythropoietin (Epo)
receptor ED and the TM/CD regions of constitutively active
TbRI(T204D) demonstrated a requirement for Epo-induced dimer-
ization of the chimeric receptors for growth-inhibitory signaling
[103]. Studies employing small-molecule dimerizers to oligomerize
the CDs ofmyristoylatedmembrane-tethered TbRI(T204D) have led
to similar conclusions [104]. Moreover, complementation studies
showed that a kinase-defective TbRI mutant can complement the
function of an activation-defective TbRI mutant by rescuing its
TbRII-dependent phosphorylation, implying that in the TbRI/TbRII
heterocomplex, two TbRI molecules must interact with each other
for signaling [105]. This notion is in accord with the report that
TbRII coexpressed with the TbRII-ED/TbRI-CD chimera failed to sig-
nal after ligand-induced dimerization, whereas coexpression of
TbRI-ED/TbRII-CDwith TbRII-ED/TbRI-CD chimeras (which can pro-
duce a heterotetramer after binding of TGF-b1) was capable of sig-
naling [106]. For TbRII, there is evidence that homodimerization has
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phosphorylation on Ser409 (stimulatory) or on Ser416 (inhibitory)
[107]. In contrast, a recent study [97] reported that a mutant TGF-
b3 dimeric ligand with only one binding-competent protomer
was capable of signaling, albeit 2- to 4-fold weaker than native
TGF-b3. Since the artiﬁcial TGF-b3 ligand could only induce TbRI/
TbRII heterodimers, these data were interpreted to indicate that
such heterodimers can function nearly autonomously of each other.
However, it is unclear whether this phenomenon holds for the na-
tive ligand, and at least part of the observed signaling could arise
from binding of the TGF-b3 mutant to heterotetrameric TGF-b
receptor PFCs.
3.2. BMP receptors
The existence of type I and type II BMP receptors and their abil-
ity to interact with one another were originally demonstrated by
several types of experiments, including radiolabeled ligand bind-
ing/crosslinking, co-immunoprecipitation and yeast two-hybrid
assays [70,71,74,75]. Similar to the observations on TGF-b signaling
and its dependence on TbRI/TbRII coexpression, joint expression of
type I and type II BMP receptors was shown to be required for tran-
scriptional activation by BMP receptor ligands, suggesting that
heterocomplex formation between the two BMP receptor types is
essential for BMP signaling [15,16,70,71,74,75]. The characteristic
pattern underlying TGF-b signaling, where TbRI needs to undergo
transphosphorylation by TbRII to become activated [15,16], is re-
tained by the BMP receptors. Yet, a distinct difference from the
TGF-b receptor system is that for most BMP ligands (including
BMP-2 and BMP-4), BMPRI rather than BMPRII displays a higher
afﬁnity for the ligand, and the ratio between the afﬁnities of the
two BMP receptor types is signiﬁcantly less pronounced than be-
tween the respective TGF-b receptors [5,23,79,81].
Heteromeric complexes between endogenous BMPRII and
BMPRIA or BMPRIB have been detected by co-immunoprecipitation
and afﬁnity labeling/immunoprecipitation experiments in several
cell types; these studies also detected populations of heterocom-
plexes that exist prior to ligand binding (PFCs; [83,108]). Following
these initial observations, immunoﬂuorescence co-patching stud-
ies were employed to quantify the above interactions and to broad-
en the studies to include homomeric BMP receptor complexes
[83,108,109]. In the absence of ligand, the % homodimerization lev-
els measured in these experiments for both BMPRI and BMPRII
were markedly lower than those measured for the respective
TGF-b receptors (compare panels A and B in Fig. 2). BMP-2 addition
increased the % homodimerization of BMPRIA and BMPRIB as de-
tected by co-patching from 5–10% to 40%, a value close to that
found for the TGF-b receptors following TGF-b1 binding. However,
BMP-2 had a much weaker effect on BMPRII homodimerization, as
expected in view of the weak afﬁnity of singly-expressed BMPRII
for BMP-2 (Fig. 2B). Notably, a substantial fraction of heteromeric
BMPRIA/BMPRII and BMPRIB/BMPRII PFCs was detected already
in the absence of ligand. Following incubation with BMP-2, the
fraction of heterocomplexes was increased by 2- to 3-fold. The li-
gand-mediated enhancement in type I/type II BMP receptor oligo-
merization points to the formation of BMP-induced heteromeric
signaling complexes in addition to the PFCs (Fig. 2B).
We have recently employed the patch/FRAP approach to
complement the co-patching studies and to explore the interaction
dynamics (stable vs. transient) in the different BMP receptor
complexes [110]. Notably, whereas the homomeric BMP receptor
complexes were stable (Rf of the uncrosslinked coexpressed recep-
tor was reduced, while its D value was unaffected) on the FRAP time
scale (minutes) both in the absence and presence of ligand, the het-
eromeric complexes were transient (Dwas reduced) either without
or with ligand [110]. This situation contrasts with that encounteredfor the TGF-b receptor oligomers, where both the homomeric and
heteromeric complexes were stable for the duration of the FRAP
experiment [56]. These ﬁndings are in accord with crystallographic
data on the type I/type II receptor EDs in complex with ligand
[23,61,62,81,82] (see Section 4), which show a direct contact be-
tween the TbRI and TbRII EDs in the ligand-bound TGF-b receptor
heterotetrameric complex, but not in the respective BMP receptor
complex (Fig. 4). The direct TbRI/TbRII contact may underlie the
higher stability of the ligand-bound heteromeric TGF-b receptor
vs. BMP receptor complexes (Fig. 4). In the case of the BMP recep-
tors, the % oligomerization can be calculated only for the homomer-
ic complexes, because this calculation is based on the reduction in
Rf as derived from the patch/FRAP experiment (see Section 3.1 and
Fig. 1), while the transient nature of the heteromeric BMP receptor
complexes results in effects onD but not on Rf. Notably, the % homo-
dimerization values calculated for BMP receptors from the patch/
FRAP studies were all markedly higher than those derived from
the co-patching experiments (Fig. 2B). This indicates that although
the homomeric complexes are stable when measured on the patch/
FRAP time scale (minutes), they are transient over a longer time
scale, and undergo substantial dissociation during the longer incu-
bation times (over 1.5 h) in the co-patching experiments. In con-
trast, the greater stability of all the TGF-b receptor complexes is
evident from the comparable values derived for their % oligomeri-
zation from the co-patching and patch/FRAP studies.
The functions of homomeric complex formation among BMP
receptors have yet to be fully explored. One such function might
be to limit the formation of heteromeric PFCs, which may already
engage in a low level of signaling in the absence of ligand. This no-
tion, although still speculative, is supported by the ﬁnding that the
formation of BMPRIB/BMPRII heterocomplexes comes at the ex-
pense of BMPRII/BMPRII homomeric complexes [110]. A second
possible role for homomeric interactions in BMP signaling comes
from studies on the signaling properties of BMP-2 mutants, where
a BMP-2 mutant that binds to only one of the two BMP binding
sites on BMPRII does not signal [111]. These results indicate that
a BMP-signaling receptor complex requires that two BMPRIIs be
bound to the dimeric ligand [111].
Another interesting observation was that the ligand-mediated
BMP receptor heterocomplexes and the BMP receptor PFCs display
distinct signaling responses. Thus, while the BMP-mediated hete-
rocomplexes transduce non-Smad signals such as p38 MAPK and
alkaline phosphatase activation, BMPRI/BMPRII PFCs are associated
with Smad signaling [15,83,108]. This indicates that the BMP
receptors manifest two modes of heterocomplex formation. Fur-
thermore, induction of diverse signaling responses implies that
the signaling receptor heterocomplexes must differ in composition.
Such a phenomenon may stem from: (i) differential association
with co-receptors or auxiliary factors; and (ii) localization to dis-
tinct membrane domains or cellular compartments. This notion
is in line with the report that PFC signaling is associated with clath-
rin-mediated endocytosis, while signaling from BMP-mediated
oligomers is correlated with caveolar uptake [112]. Although pos-
sible differences between signaling by PFCs and by ligand-induced
complexes have not been investigated for the TGF-b receptors, a re-
port that the cholesterol content of the plasma membrane modu-
lates the ratio of TGF-b1 crosslinking to TbRI vs. TbRII suggests
that the membrane lipid composition might alter the quaternary
structure of the ligand-binding complex [113].
4. Structural aspects of TGF-b and BMP receptor
oligomerization: crystallographic studies
TGF-b and BMP receptors and ligands show an overall structural
similarity; yet, a remarkable speciﬁcity in receptor–ligand interac-
tions is observed [11,23,25]. Whereas ligand binding of TbRII is
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BMP (BMPRII) and activin (ActRII and ActRIIB) receptors
[16,37,62,114]. The molecular basis for these differences can be
revealed by high-resolution structural analysis of the receptors
relative to their ligand-bound complexes.
Structurally, the subunits of the TGF-b [57–60,115] or BMP/GDF
[64,81,82,116–120] dimeric ligands can be envisaged as slightly
curved left hands, with the thumb representing a-helix 1 and the
wrist representing helix 3 of each protomer. The four ﬁngers of
the hand are formed by two antiparallel b-sheets, and six cysteines
are linked in a cystine-knot conformation [121]. In most of these
dimeric ligands, the dimer is stabilized by a disulﬁde bond that
links the two protomers in the wrist region, aided by hydrophobic
interactions [57,59,60]. The reported existence of TGF-b3 in an
additional ‘‘open’’ conformation [115] is not supported by the
recently observed structure of the ternary complex between the
ligand and the EDs of the two receptor types, and is incompatible
with the binding of TGF-b3 to TbRI (ALK5) in the TGF-b3/TbRII/TbRI
ED complex [61,62].
Crystal structures of the ED of TbRII, alone or in complex with
TGF-b3 [115,122], and the NMR solution structure of the TbRII
ED [123], have been resolved. For type II receptors that bind BMPs,
the structures of the EDs of ActRII and ActRIIB, as well as the ActRII
ED in complex with BMP-7, have been determined [64,124,125].
Also resolved was the crystal structure of the ED of BMPRIA in
complex with BMP-2 [117]. The EDs of the TGF-b and BMP recep-
tors display a three-ﬁnger toxin fold, initially identiﬁed in ActRII
[124], with ﬁngers 1 and 3 presenting some deviations (see
Fig. 4). TbRII binds to the ﬁngertips of one TGF-b monomer in a
wedge-like manner. Interactions between the base of the TbRII tox-
in ﬁngers and the TGF-b ﬁngers are mainly polar. Notably, unlike
the previously reported open conformation of TGF-b3 bound to
TbRII alone [115], neither the TbRII ED nor TGF-b undergo signiﬁ-
cant conformational changes in the context of ternary heteromeric
complex formation between TGF-b3 or TGF-b1 and the EDs of TbRII
and TbRI [61,62]. Unlike the binding of TbRII to TGF-b, ActRII binds
BMP-7 at the ‘‘knuckle’’ region of the dimeric ligand [54,64], in
agreement with the concept that binding to type II receptors is a
major determinant of ligand speciﬁcity. The ED of BMPRIA contacts
both ligand subunits through binding to the ‘‘wrist’’ epitope
formed by the two protomers of the BMP-2 dimer [117]. These fea-
tures were proposed to be common to all type I receptors of the
TGF-b superfamily [54]. In line with this notion, the binding of
the TbRI ED to the wrist epitope, where it contacts the two TGF-b
subunits, was recently reported [61,62]. However, structural
differences between the BMP and TGF-b wrist epitopes and their
corresponding sites of interaction with the receptors prevent
cross-recognition between TGF-b ligands and type I BMP receptors,
and vice versa [61,62]. Structures of the complexes between BMP-2
and TGF-b1 with the EDs of their respective type I and type II
receptors are depicted in Fig. 4. As reported for TbRII ED and
TGF-b ligands, the conformations of BMP ligands (BMP-7 or
BMP-2) and the EDs of the receptors with which they form com-
plexes do not undergo alterations following their binding
[64,81,82,117,124].
Crystallographic studies have resolved the structures of ternary
heterocomplexes comprising the EDs of TbRI and TbRII together
with either TGF-b3 or TGF-b1 [61,62]. The complexes (2:2:2
stoichiometry; see Fig. 4) are characterized by three paired interac-
tions: (i) TGF-b/TbRI, where TbRI binds to both subunits of the TGF-
b dimeric ligand; (ii) TGF-b/TbRII; and notably (iii) TbRI/TbRII,
where the EDs of these receptors are in direct physical contact.
The TGF-b/TbRII interaction forms a composite binding interface
capable of binding TbRI with signiﬁcantly increased afﬁnity
[61,62]. Notably, these interactions may underlie the cooperativity
between TbRII and the TGF-b ligand in recruiting TbRI to theheteromeric receptor complex (see Section 2). Despite the marked
resemblance between heteromeric complexes of the EDs of BMP
type I and type II receptors to those of the TGF-b receptors, their
EDs do not contact each other directly [23,81,82], in line with a
non-cooperative mode of assembly for the receptor EDs.
Crystallographic structural data on receptor CDs are available for
TbRI [126,127] as well as for the kinase domain of ActRIIB [128].
Also recently added to the Protein Data Bank (PDB) are the CD struc-
tures of other TGF-b-family receptors (ALK1, ALK2, FKBP12-bound
ALK6, and BMPRII; PDB ID 3MY0, 3Q4U, 3MDY, and 3G2F, respec-
tively). The TbRI and ActRIIB CD structures demonstrate that the
protein kinase domains of these receptors resemble the catalytic
center of tyrosine kinases [129], supporting the notion that recep-
tors of the TGF-b superfamily are dual-speciﬁcity (Ser/Thr as well
as Tyr) kinases [130–132]. The crystal structure of the unphosphor-
ylated CD of TbRI complexed with an inhibitor of TGF-b signaling
(the immunophilin FKBP12) reﬂects the catalytically inactive con-
formation of this CD, which occurs due to rotation of the N-lobe rel-
ative to the C-lobe; FKBP12 binds to the Gly/Ser-rich (GS) domain of
TbRI, blocking access to phosphorylation sites in the GS region and
thus stabilizing the inactive conformation [126]. The inhibitory
interactions between the GS region and the kinase domain in the
unphosphorylated TbRI CD are abolished in the absence of FKBP12.
Furthermore, phosphorylation of one Thr and three Ser residues
transforms the GS region from a site that binds FKBP12 to a surface
that interacts with a basic patch on Smad2, a TbRI phosphorylation
target [127]. Notably, a search for potential dimers in the TbRI CD/
FKBP12 crystal lattice based on its non-crystallographic symmetry
suggested a potential TbRI homodimer, whose contact regions do
not depend on FKBP12, and where the N-termini of both subunits
are oriented in the same direction, as required for membrane teth-
ering of the receptors [126].
5. Concluding remarks
Oligomeric interactions between TGF-b superfamily receptors
have the potential to regulate signaling in a variety of cellular
and biological systems on a nearly-immediate time scale. Both
the TGF-b and BMP receptors are present at the cell surface as a
mixture of monomeric, homodimeric and heteromeric complexes
even in the absence of ligand, and the relative levels of the different
oligomeric complexes can be further modulated by ligand binding
(see model in Fig. 5). These features have important potential con-
sequences for signaling diversity. Thus, signaling may be initiated
not only from ligand-induced heterocomplexes (Fig. 5A), but also
from PFCs (Fig. 5B). These two activation modes may stem from
different molecular compositions of the two types of heterocom-
plexes (e.g., association with distinct co-receptors or scaffold pro-
teins), and/or from their localization in different cellular
compartments. This hypothesis is supported by data on the effects
of co-receptors such as TbRIII and endoglin on the TGF-b and BMP
receptor systems. Thus, numerous studies provide evidence that
these proteoglycan co-receptors can complex with the type I and
type II TGF-b or BMP receptors, and modulate signaling via mech-
anisms that in many cases involve targeting to scaffold proteins (b-
arrestin2 or GIPC) and regulate the trafﬁcking and localization of
the signaling receptors [133–136]. Accordingly, PFCs and ligand-
mediated BMP receptor heterocomplexes were shown to stimulate
different signaling pathways [83,108,112]. The PFCs appear to have
an inherent, albeit weak, signaling capability already prior to li-
gand binding, which is clearly apparent when the receptors are
overexpressed; this activity is substantially increased upon ligand
binding ([5,101,108,110,137]; see model in Fig. 5B). This suggests
that the heteromeric PFCs undergo a conformational change fol-
lowing ligand binding, which elevates the phosphorylation of the
type I receptor by the type II kinase (proposed to involve reorien-
Fig. 5. Model for signaling through ligand-mediated receptor hetero-oligomers and
preformed complexes (PFCs). For simplicity, the model depicts the BMP receptors,
and the features that are different for the TGF-b receptors are addressed at the
bottom. (A) Ligand-mediated signaling complexes. The cell-surface receptor pop-
ulation is comprised of monomers, homodimers, and heterotetramers. Heterodi-
mers may also form (not depicted in the ﬁgure), at least with artiﬁcial ligands [97].
The initial step is binding of BMP to its higher-afﬁnity receptor (BMPRI for most
BMP ligands); the binding can be either to BMPRI homodimers or sequentially to
two BMPRI protomers, inducing their dimerization. Notably, the various BMP
receptor oligomers display a dynamic nature, both without and with ligand
(depicted by bidirectional arrows). The transient interactions limit the lifetime of
the heterocomplexes, and contribute to the ﬂexibility of the BMP system. (B) BMP
receptor heterotetramers form prior to ligand binding. Because homodimerization
of BMPRII has the potential to compete with heteromeric complex formation [110],
it is possible that BMPRII monomers are preferentially recruited to the hetero-
oligomers, while BMPRII homodimerization fulﬁlls an inhibitory role. In such a case,
heterocomplex formation is likely to occur by recruitment of individual protomers
of e.g. BMPRII to homodimers of BMPRI (or vice versa). Although association of a
BMPRII homodimer with a BMPRI homodimer cannot be excluded, it would require
a major conformational change in the ED regions such that the homodimeric
contacts are lost (see Fig. 4). The heteromeric PFCs can signal to a low degree (single
lightning arrow) without ligand, but ligand binding alters the PFC conformation and
enhances signaling (two lightning arrows). In addition, the ligand-mediated
increase in signaling from PFCs may include a contribution from stabilization of
the heterocomplex by the ligand. Of note, there may be differences between the
pathways activated by PFCs vs. BMP-induced heterocomplexes [83]. Heterocomplex
formation among the TGF-b receptors follows an analogous pattern, but with some
distinct differences: (i) the high-afﬁnity receptor that binds the ligand initially is
the type II receptor (TbRII); (ii) in view of the higher stability of TGF-b receptor
oligomers as compared to the BMP receptors, the bidirectional arrows indicating
the formation of homodimers and heteromeric complexes become nearly unidi-
rectional for the TGF-b receptors.
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[137]), and enhances type I receptor activity (Fig. 5B).
The ability of the PFCs to signal without ligand necessitates
mechanisms that can dampen ligand-independent responses. For
the TGF-b receptors, FKBP12 was shown to attenuate signaling of
unliganded receptors by locking TbRI in an inactive conformation,
while TGF-b-mediated phosphorylation of TbRI by TbRII eliminated
the FKBP12 binding site [126,127]. FKBP12 can also bind to
BMPRIA, BMPRIB and ActRI (ALK2, which functions as a type I
BMP receptor), and mutations in these receptors that interfere with
FKBP12 binding resulted in detectable constitutive activation
[138–140]. However, the detailed mechanism of the inhibition of
BMP signaling by FKBP12 has yet to be established. Notably, BMP
signaling from heteromeric PFCs was recently shown to be damp-
ened by the transient nature of BMP receptor heteromeric com-
plexes (Figs. 2 and 5B); this transience limits the ‘‘mutual
residence’’ time of BMPRI with the type II receptors in the hetero-
meric complex, reducing the probability for excessive activation
(Fig. 5). Furthermore, the recent ﬁnding that heteromeric BMP
receptor complexes form at the expense of BMPRII homodimers
gave rise to the proposal that such a competition between homo-
and hetero-oligomerization may suppress ligand-independent sig-
naling by heteromeric PFCs ([110]; Fig. 5B).
Association of receptor homodimers into the hexameric recep-
tor–ligand complex is most likely accompanied by alteration in
the relative positioning of the receptor EDs, since there is no
detectable direct contact between the EDs of the same receptors
in the crystal structures of the ternary heterocomplexes
([23,61,62,81,82]; see Fig. 4). Importantly, the heterocomplexes of
the BMP receptors are much more transient than those of the
TGF-b receptors, even in the presence of ligand (Fig. 2). Therefore,
heterocomplex formation among the BMP receptors follows a dy-
namic equilibrium between receptor monomers, homodimers and
heteromeric complexes, implying the potential existence of several
different routes to achieve the ﬁnal hexameric ligand-containing
signaling complex (Fig. 5). On the other hand, the oligomers formed
among the TGF-b receptors are much more stable, as indicated by
their negligible dissociation on the time scales of the patch/FRAP
and co-patching experiments. The interplay between ligand-in-
duced heterocomplexes and PFCs (Fig. 5) has potential important
roles in biological signaling. Thus, the multiple binding sites of
the heteromeric PFCs would result in high avidity for the ligands
relative to monomeric or dimeric receptors. This in turn may lead
to preferential signaling from PFCs at low ligand concentrations.
At higher concentrations, the balance would shift towards signaling
from ligand-induced complexes. A regulatory mechanism of this
typemay have important implications for the formation ofmorpho-
genic gradients in development.
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